Form 4: Acrivon Therapeutics Chief Accounting Officer Reports Tax Withholding Transaction
SEC Form 4 Filing
Katharine Peterson, Chief Accounting Officer of Acrivon Therapeutics, reports a transaction involving the withholding of shares to cover tax obligations.
Summary
- On May 14, 2025, Katharine Peterson, the Chief Accounting Officer of Acrivon Therapeutics, Inc., reported a transaction on Form 4.
- The transaction involved the withholding of 99 shares of common stock at a price of $1.14 per share to satisfy mandatory tax withholding requirements upon the vesting of restricted stock units.
- Following the transaction, Peterson directly owns 4,320 shares of Acrivon Therapeutics common stock.
Sentiment
Score: 7
Explanation: The document is a standard regulatory filing related to tax withholding, which is neither particularly positive nor negative. It reflects normal corporate operations.
Industry Context
Form 4 filings are a routine part of compliance for corporate insiders and provide transparency into their transactions in company stock. This transaction is related to tax obligations arising from vested stock units, a common form of executive compensation.
Key Dates
| Date | Description |
|---|---|
| 05/14/2025 | Date of transaction (share withholding for tax obligations). |
| 05/16/2025 | Date of signature on the report. |
Keywords
Form 4, Acrivon Therapeutics, Katharine Peterson, Chief Accounting Officer, Tax Withholding, Beneficial Ownership, ACRV, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.